-
Je něco špatně v tomto záznamu ?
The role of AMPK/mTOR signaling pathway in anticancer activity of metformin
N. Chomanicova, A. Gazova, A. Adamickova, S. Valaskova, J. Kyselovic
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
PubMed Central
od 2020
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- MeSH
- apoptóza účinky léků MeSH
- hypoglykemika terapeutické užití MeSH
- lidé MeSH
- metformin škodlivé účinky terapeutické užití MeSH
- nádory farmakoterapie enzymologie patologie MeSH
- přehodnocení terapeutických indikací léčivého přípravku MeSH
- proteinkinasy aktivované AMP metabolismus MeSH
- protinádorové látky škodlivé účinky terapeutické užití MeSH
- signální transdukce MeSH
- TOR serin-threoninkinasy metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Metformin (MTF) is a widely used drug for the treatment of diabetes mellitus type 2 (DM2) and frequently used as an adjuvant therapy for polycystic ovarian syndrome, metabolic syndrome, and in some cases also tuberculosis. Its protective effect on the cardiovascular system has also been described. Recently, MTF was subjected to various analyzes and studies that showed its beneficial effects in cancer treatment such as reducing cancer cell proliferation, reducing tumor growth, inducing apoptosis, reducing cancer risk in diabetic patients, or reducing likelihood of relapse. One of the MTF's mechanisms of action is the activation of adenosine-monophosphate-activated protein kinase (AMPK). Several studies have shown that AMPK/mammalian target of rapamycin (mTOR) pathway has anticancer effect in vivo and in vitro. The aim of this review is to present the anticancer activity of MTF highlighting the importance of the AMPK/mTOR pathway in the cancer process.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22007912
- 003
- CZ-PrNML
- 005
- 20220323102115.0
- 007
- ta
- 008
- 220309s2021 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.934618 $2 doi
- 035 __
- $a (PubMed)34062070
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Sabová, Nikola, $d 1993- $7 xx0267320 $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Slovakia
- 245 14
- $a The role of AMPK/mTOR signaling pathway in anticancer activity of metformin / $c N. Chomanicova, A. Gazova, A. Adamickova, S. Valaskova, J. Kyselovic
- 504 __
- $a Literatura
- 520 9_
- $a Metformin (MTF) is a widely used drug for the treatment of diabetes mellitus type 2 (DM2) and frequently used as an adjuvant therapy for polycystic ovarian syndrome, metabolic syndrome, and in some cases also tuberculosis. Its protective effect on the cardiovascular system has also been described. Recently, MTF was subjected to various analyzes and studies that showed its beneficial effects in cancer treatment such as reducing cancer cell proliferation, reducing tumor growth, inducing apoptosis, reducing cancer risk in diabetic patients, or reducing likelihood of relapse. One of the MTF's mechanisms of action is the activation of adenosine-monophosphate-activated protein kinase (AMPK). Several studies have shown that AMPK/mammalian target of rapamycin (mTOR) pathway has anticancer effect in vivo and in vitro. The aim of this review is to present the anticancer activity of MTF highlighting the importance of the AMPK/mTOR pathway in the cancer process.
- 650 _2
- $a proteinkinasy aktivované AMP $x metabolismus $7 D055372
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x škodlivé účinky $x terapeutické užití $7 D000970
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a přehodnocení terapeutických indikací léčivého přípravku $7 D058492
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoglykemika $x terapeutické užití $7 D007004
- 650 _2
- $a metformin $x škodlivé účinky $x terapeutické užití $7 D008687
- 650 _2
- $a nádory $x farmakoterapie $x enzymologie $x patologie $7 D009369
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a TOR serin-threoninkinasy $x metabolismus $7 D058570
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Gažová, Andrea, $d 1980- $7 xx0255822 $u Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University Bratislava, Slovakia
- 700 1_
- $a Samáková, Adriana, $d 1993- $7 xx0267319 $u 5th Department of Internal Medicine, Faculty of Medicine, Comenius University Bratislava, Slovakia
- 700 1_
- $a Valaskova, S. $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Slovakia
- 700 1_
- $a Kyselovič, Ján, $d 1963- $7 xx0082943 $u 5th Department of Internal Medicine, Faculty of Medicine, Comenius University Bratislava, Slovakia
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 70, č. 4 (2021), s. 501-508
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34062070 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y p $z 0
- 990 __
- $a 20220309 $b ABA008
- 991 __
- $a 20220323102110 $b ABA008
- 999 __
- $a ok $b bmc $g 1773042 $s 1159105
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 70 $c 4 $d 501-508 $e 20210601 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- LZP __
- $b NLK118 $a Pubmed-20220309
